Webinar presenters David Chi, PhD, Director of Oncology Product Management, Thermo Fisher Scientific, and Gary Pestano, PhD, Chief Development Officer, Biodesix, Inc., and Bence Sipos, MD, Molecular Pathology, Baden-Württemberg, Stuttgart, Germany, discusses the rapidly evolving field of precision oncology, the increasing availability of targeted treatments offers renewed hope to patients. Unfortunately, the lengthy wait for next-generation sequencing (NGS) results—often weeks—and the risk of insufficient sample quantity (QNS) can diminish this hope. In this webinar we will introduce the newly FDA-approved Oncomine Dx Express Test is set to revolutionize this process. Approved for companion diagnostics (CDx) and tumor profiling, this test is capable of being implemented in even labs without NGS, expertise close to patients, and it delivers results as fast as in 24 hours, from tissue sample to report.
This on-demand webinar was originally broadcast on August 27, 2025.
What will this webinar empower you to do?
• Learn all about the Oncomine Dx Express Test which comes as an end to end
solution on the Ion Torrent Genexus Dx System
• Hear about first experience with the performance in a US laboratory which
collaborated on the test validation
• Understand the impact of rapid profiling services by laboratories using this
solution in local community settings, drawing on experiences from Germany
• Ask questions of our distinguished presenters
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific.